SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

R1487 (hydrochloride)

Item No. 31478

CAS Registry No.:	449808-64-4
Formal Name:	6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl) amino]-pyrido[2,3-d]pyrimidin-7(8H)-one, monohydrochloride
MF:	$C_{19}H_{18}F_2N_4O_3$ • HCl
FW:	424.8
Purity:	≥98%
UV/Vis.:	λ_{max}: 299, 349 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

R1487 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the R1487 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. R1487 (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of R1487 (hydrochloride) in these solvents is approximately 1 mg/ml.

R1487 (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, R1487 (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. R1487 (hydrochloride) has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

R1487 is an inhibitor of p38α MAPK (IC_{50} = 10 nM).[1] It is selective for p38α over p38β MAPK (K_ds = 0.2 and 29 nM, respectively), as well as a panel of 306 additional kinases at 10 µM, but does inhibit 11 kinases by greater than 85% at 10 µM. R1487 inhibits LPS-induced IL-1β production in isolated human whole blood (IC_{50} = 170 nM). It also inhibits LPS-induced production of TNF-α and IL-6 in rats (ED_{50}s = 0.8 and 0.4 mg/kg). R1487 reduces yeast-induced hyperalgesia in rats (ED_{50} = 5.5 mg/kg).

Reference

1. Goldstein, D.M., Soth, M., Gabriel, T., *et al.* Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase. *J. Med. Chem.* **54(7)**, 2255-2265 (2011).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM